ArticleAnnals of the rheumatic diseases2007
Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.
Article in Annals of the rheumatic diseases, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review.Clinical rheumatology · 2012Pooled it
- Myocarditis in connective tissue diseases: an often-overlooked clinical manifestation.Rheumatology international · 2023Review
- Intravenous Immunoglobulin in Idiopathic Inflammatory Myopathies: a Practical Guide for Clinical Use.Current rheumatology reports · 2023Review
- A rare form of dermatomyositis associated with muscle weakness and normal creatine kinase level.BMJ case reports · 2020Article
- Recovering autonomy is a key advantage of home-based immunoglobulin therapy in patients with myositis: A qualitative research study.Medicine · 2020Article
- Current Treatment for Myositis.Current treatment options in rheumatology · 2018Review
- Th17 cells reflect colon submucosal pathologic changes in active eosinophilic granulomatosis with polyangiitis.BMC immunology · 2015Article
- Rituximab as a first-line agent for the treatment of dermatomyositis.Rheumatology international · 2012Article
- Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution?Rheumatology international · 2012Article
- Intravenous immunoglobulin therapy in rheumatic diseases.Nature reviews. Rheumatology · 2011Review
- Pathogenesis, classification and treatment of inflammatory myopathies.Nature reviews. Rheumatology · 2011Review
- Favorable outcome of juvenile dermatomyositis treated without systemic corticosteroids.The Journal of pediatrics · 2010Article
- A longitudinal, integrated, clinical, histological and mRNA profiling study of resistance exercise in myositis.Molecular medicine (Cambridge, Mass.)Article
- Intravenous immune globulin suppresses angiogenesis in mice and humans.Signal transduction and targeted therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe study was conducted with the aim of achieving an improved understanding of the molecular mechanisms of high-dose intravenous immunoglobulin (IVIG) in inflammatory myopathies by investigating the effects on muscle function and immunological molecules in skeletal muscle of polymyositis (PM), dermatomyositis (DM) and inclusion body myositis (IBM) patients.
methodsThirteen treatment-resistant patients, 6 PM, 4 DM, 2 IBM and 1 juvenile DM, were treated with 2 g/kg of IVIG, three times at monthly intervals. Functional Index in Myositis and serum creatinine kinase (CK) levels were determined, and muscle biopsies were performed before treatment and after the third IVIG infusion. Immunological molecules were also studied in biopsies taken 24-48 h after the first infusion.
resultsImproved muscle function was observed in three patients (1 PM, 1 DM and 1 IBM) and CK levels decreased in five. T cells, macrophages, major histocompatibility complex (MHC) class I antigen on muscle fibres, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) expression and membranolytic attack complex (MAC) deposits on capillaries were present to an equal degree in biopsies before and after IVIG treatment. No correlation between the clinical response and molecular changes was found.
conclusionsThe clinical effects of high-dose IVIG on muscle function in patients with refractory inflammatory active myositis did not correspond to effects on any of the investigated molecules in our study. T cells, macrophages, phenotypical changes in muscle fibres and endothelial cell activation were still present after treatment. These observations question a role for IVIG as an immune-modulating therapy in patients with inflammatory myopathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.